Expect Trikafta to Bring Big Changes in Treating Cystic Fibrosis
October 2021
Trikafta (elexacaftor/tezacaftor/ivacaftor) will be a game changer for treating cystic fibrosis (CF).
It targets a gene mutation found in nearly 90% of CF patients.
Other CF transmembrane conductance regulator (CFTR) modulators...Kalydeco, Orkambi, and Symdeko...target genetic mutations found in fewer than 50% of patients.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive